TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases

AMERICAN JOURNAL OF HEMATOLOGY

WILEY

1. Associazione Italiana Ricerca sul Cancro (AIRC) [9980, 21198, IG-21687, IG-5506]
2. AIRC [16695]
3. Fondazione CaRiCal [16695]
4. Ricerca Finalizzata, Ministero della Salute, Rome, Italy [PE 2016-02362756]
5. Progetto Ricerca Finalizzata, Ministero della Salute, Rome, Italy [RF-2018-12365790]
6. Compagnia S. Paolo, Turin, Italy [2017.0526]
7. Ministry of Health (Project 5 x1000)
8. AIRC 5 x1000, Associazione Italiana per la Ricerca sul Cancro Foundation Milan, Italy [21198]
9. Swiss Cancer League, Bern, Switzerland [3746, 4395 4660, 4705]
10. European Research Council (ERC) Consolidator Grant CLLCLONE [772051]
11. Swiss National Science Foundation, Berne, Switzerland [320030_169670/1, 310030_192439]
12. Leukemia & Lymphoma Society, Translational Research Program, New York [6594-20]
13. GILEAD Sciences Srl.
14. Swiss National Science Foundation (SNF) [310030_192439] Funding Source: Swiss National Science Foundation (SNF)
15. European Research Council (ERC) [772051] Funding Source: European Research Council (ERC)